A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors
收藏NIAID Data Ecosystem2026-03-08 收录
官方服务：
资源简介：
The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single agent when given orally to adult patients with advanced solid tumors that have progressed despite standard therapy, or where there is no standard therapy.
创建时间：
2015-04-15
